Lv21
180 积分 2023-08-16 加入
CoadministeredCagrilintideandSemaglutideinAdultswithOverweightorObesity
2分钟前
待确认
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
11分钟前
求助中
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
8天前
已完结
Real-World Multicenter Registry to Determine Management and Quality of Care of Patients with Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases in China (iCaReMe China)
6个月前
已完结
Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: a randomized controlled trial
8个月前
已完结
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials
9个月前
已完结
Study design and baseline profile for adults with type 2 diabetes in the onceweekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
11个月前
已关闭
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis
1年前
已完结
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
1年前
已完结
eroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside
1年前
已完结
皖公网安备34019202002308
